SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 46, 2014, Pages 16586-16591

  Luo, Hong Bin ^a   Xia, Yi Yuan ^a   Shu, Xi Ji ^b   Liu, Zan Chao ^a   Feng, Ye ^a   Liu, Xing Hua ^a   Yu, Guang ^a   Yin, Gang ^a   Xiong, Yan Si ^a   Zeng, Kuan ^a   Jiang, Jun ^a   Keqiang, Y K ^c   Wang, Xiao Chuan ^a,d   Wang, Jian Zhi ^a,d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JIANGHAN UNIVERSITY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PEPTIDES AND PROTEINS; PROTEIN K340; SUMO 1 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-40]; ANDROSTANE DERIVATIVE; BISINDOLYLMALEIMIDE I; GINKGOLIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HYBRID PROTEIN; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; MAPT PROTEIN, HUMAN; MAPT PROTEIN, RAT; NERVE PROTEIN; PEPTIDE FRAGMENT; PROTEASOME; SALICYLIC ACID DERIVATIVE; SUMO1 PROTEIN, HUMAN; WORTMANNIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; SUMOYLATION; UBIQUITINATION; AMINO ACID SUBSTITUTION; ANIMAL; FEMALE; GENETICS; HEK293 CELL LINE; HIPPOCAMPUS; MALE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; PHOSPHORYLATION; POINT MUTATION; PROTEIN PROCESSING; SITE DIRECTED MUTAGENESIS; SOLUBILITY; SPRAGUE DAWLEY RAT;

RATTUS;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PEPTIDES; ANDROSTADIENES; ANIMALS; CEREBRAL CORTEX; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HIPPOCAMPUS; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POINT MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SALICYLATES; SOLUBILITY; SUMO-1 PROTEIN; SUMOYLATION; TAU PROTEINS; UBIQUITINATION;

EID: 84915749668     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417548111     Document Type: Article

References (55)

1. Iqbal K, et al. (1986) Defective brain microtubule assembly in Alzheimer's disease. Lancet 2(8504):421-426
2. Koh JY, Yang LL, Cotman CW (1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533(2):315-320
3. Selkoe DJ (1994) Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol 53(5):438-447
4. Iqbal K, Alonso AdelC, Grundke-Iqbal I (2008) Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J Alzheimers Dis 14(4):365-370
5. Iqbal K, Grundke-Iqbal I (1991) Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease. Mol Neurobiol 5(2-4): 399-410
6. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12(1):38-55
7. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91(12):5562-5566
8. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2(7):783-787
9. Dorval V, Fraser PE (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281(15):9919-9924
10. Dorval V, Fraser PE (2007) SUMO on the road to neurodegeneration. Biochim Biophys Acta 1773(6):694-706
11. Takahashi K, Ishida M, Komano H, Takahashi H (2008) SUMO-1 immunoreactivity colocalizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci Lett 441(1):90-93
12. Köpke E, et al. (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268(32): 24374-24384
13. Dolan PJ, Johnson GV (2010) A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem 285(29):21978-21987
14. Hamano T, et al. (2008) Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 27(5): 1119-1130
15. Bednarski E, Lynch G (1996) Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem 67(5):1846-1855
16. Grune T, et al. (2010) Tau protein degradation is catalyzed by the ATP/ubiquitinindependent 20S proteasome under normal cell conditions. Arch Biochem Biophys 500(2):181-188
17. Petrucelli L, et al. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13(7):703-714
18. Butler D, Nixon RA, Bahr BA (2006) Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy 2(3): 234-237
19. Nixon RA, CataldoAM, Mathews PM (2000) The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: A review. Neurochem Res 25(9-10):1161-1172
20. Nixon RA, et al. (2005) Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol 64(2):113-122
21. Grundke-Iqbal I, et al. (1988) Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments. Brain Res 464(1):43-52
22. Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235(4796):1641-1644
23. Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84(9):3033-3036
24. Hershko A, Eytan E, Ciechanover A, Haas AL (1982) Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. J Biol Chem 257(23):13964-13970
25. Wang GP, Grundke-Iqbal I, Kascsak RJ, Iqbal K, Wisniewski HM (1984) Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s). Acta Neuropathol 62(4):268-275
26. Hay RT (2005) SUMO: A history of modification. Mol Cell 18(1):1-12
27. Fukuda I, et al. (2009) Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol 16(2):133-140
28. Gong CX, et al. (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 275(8):5535-5544
29. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85(2):148-175
30. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82(2):373-428
31. Jentsch S, Pyrowolakis G (2000) Ubiquitin and its kin: How close are the family ties? Trends Cell Biol 10(8):335-342
32. Kimura T, et al. (2010) Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem 285(49):38692-38699
33. Dohmen RJ (2004) SUMO protein modification. Biochim Biophys Acta 1695(1-3): 113-131
34. Martin L, Latypova X, Terro F (2011) Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochem Int 58(4):458-471
35. Eun Jeoung L, et al. (2008) Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier. Open Biochem J 2:67-76
36. Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15(23): 2321-2328
37. Mattson MP (2001) Neuronal death and GSK-3beta: A tau fetish? Trends Neurosci 24(5):255-256
38. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9(3, suppl):309-317
39. Voronkov M, Braithwaite SP, Stock JB (2011) Phosphoprotein phosphatase 2A: A novel druggable target for Alzheimer's disease. Future Med Chem 3(7):821-833
40. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25(1):59-68
41. Peng JH, et al. (2007) Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats. Neuropharmacology 52(7):1521-1527
42. Zhu LQ, et al. (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27(45):12211-12220
43. Geschwind DH (2003) Tau phosphorylation, tangles, and neurodegeneration: The chicken or the egg? Neuron 40(3):457-460
44. Pountney DL, et al. (2003) SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol 184(1):436-446
45. Grundke-Iqbal I, et al. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83(13):4913-4917
46. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159
47. Cohen TJ, et al. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252
48. Kimura T, et al. (2008) GSK-3beta is required for memory reconsolidation in adult brain. PLoS ONE 3(10):e3540
49. Maeda S, et al. (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46(12):3856-3861
50. Song J, Zhang Z, Hu W, Chen Y (2005) Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: A reversal of the bound orientation. J Biol Chem 280(48):40122-40129
51. Mullen JR, Das M, Brill SJ (2011) Genetic evidence that polysumoylation bypasses the need for a SUMO-targeted Ub ligase. Genetics 187(1):73-87
52. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z (2000) SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101(7):753-762.
53. Fuchs SY, Lee CG, Pan ZQ, Ronai Z (2002) Cell 110(4):531
54. Desterro JM, Rodriguez MS, Hay RT (1998) SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2(2):233-239
55. Ulrich HD (2005) Mutual interactions between the SUMO and ubiquitin systems: A plea of no contest. Trends Cell Biol 15(10):525-532